CICristiana Iaculli

Cristiana Iaculli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristiana Iaculli has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epiretinal Human Amniotic Membrane Overlay for Recurrent Retinal Detachment in Highly Myopic Eyes with Peripapillary Breaks over Chorioretinal Atrophy: Surgical Technique and Outcomes

    by Federico Moscara, Giacomo Boscia, Pasquale Puzo, Pasquale Viggiano, Alba Chiara Termite, Ciro Borriello, Arcangelo Clemente, Ilaria Lolli, Marinetta Calicchio, Emanuele Crincoli, et al.

    Purpose: To evaluate the anatomical and functional outcomes of an epiretinal cryopreserved human amniotic membrane (hAM) overlay technique for the management of recurrent retinal detachment (RD) associated with peripapillary breaks in highly myopic eyes. Methods: Retrospective interventional case series including five eyes with recurrent RD (mean axial length 30.70 ± 2.03 mm). Two eyes presented with recurrence under silicone oil (SO) tamponade, and three after prior SO removal. All eyes underwent 25-gauge pars plana vitrectomy with SO removal when present. A customized 8–9 mm hAM patch was positioned epiretinally and unrolled bimanually under perfluorocarbon liquid (PFCL). Final tamponade was achieved with SO 1000 cSt, followed by scheduled SO removal. Results: Complete retinal reattachment was achieved in all cases (100%) after a single procedure and remained stable throughout follow-up. Mean best-corrected visual acuity (BCVA) improved from 1.00 ± 0.60 to 0.68 ± 0.58 logMAR at 2 months after SO removal (p = 0.068). Optical coherence tomography demonstrated stable integration of the hAM as a hyperreflective layer over the peripapillary defects. No cases of graft dislocation, proliferative vitreoretinopathy, or significant inflammatory complications were observed. Conclusions: The epiretinal hAM overlay technique appears to be a safe and effective approach for sealing complex peripapillary breaks in highly myopic eyes with chorioretinal atrophy. By providing both mechanical support and a biological scaffold for tissue repair, this technique may represent a valuable surgical option in cases where conventional retinopexy is not feasible or has failed.

  • Open Access

    Twelve-Month Outcomes and Optical Coherence Tomography (OCT) Biomarkers After Intravitreal Dexamethasone Implantation in Pseudophakic Eyes with Post-Vitrectomy Cystoid Macular Edema (CME)—Refractory to Medical Therapy

    by Francesco Pignatelli, Alfredo Niro, Giuseppe Addabbo, Pasquale Viggiano, Giacomo Boscia, Maria Oliva Grassi, Francesco Boscia, Cristiana Iaculli, Giulia Maria Emilia Clima, Antonio Barone, et al.

    Background: In this study, we evaluated the incidence of cystoid macular edema (CME) after pars plana vitrectomy (PPV) for different retinal pathologies and assessed the role of optical coherence tomography (OCT) biomarkers in guiding treatment decisions in post-surgical CME patients who were refractory to medical therapy over a follow-up period of 12 months. Methods: Medical records of consecutive pseudophakic patients, who underwent PPV for different retinal pathologies, were retrospectively evaluated in this single-center, uncontrolled study. The incidence of post-PPV CME was assessed. Eyes with post-PPV CME in the first 2 months after surgery, with available clinical and OCT data for 12 months after surgery, were included in the evaluation. The mean best-corrected visual acuity (BCVA; logMAR), mean central macular thickness (CMT; μm) change, and response to different treatments [medical therapy and intravitreal dexamethasone (DEX) implant] were evaluated 1, 3, 6, 9, and 12 months after PPV. The impact of OCT biomarkers on the exposure to DEX implants was assessed. Adverse events, potentially related to the treatment, were investigated as well. Results: Of the 346 pseudophakic patients (352 eyes) who participated in this study, 54 (54 eyes) developed CME within the first 2 months after PPV (incidence of 15.3%). Among them, 48 patients were deemed eligible for the 12-month analysis. Preoperative mean BCVA (1.44 ± 0.99 logMAR) significantly improved to 0.32 ± 0.37 logMAR after 12 months (p < 0.001). The mean baseline CMT of 347 (±123.5) μm significantly decreased to 290 μm (±80.4; p = 0.003) by the end of the follow-up. Twenty-five eyes (52%) required one or more DEX implants for CME, due to being refractory to topical therapy. Significant correlations were found between the mean CMT values at various time points. Additionally, patients who required DEX implants at months 3 and 9 were more likely to present intraretinal fluid (IRF), disorganization of inner retinal layers (DRIL), disorganization of outer retinal layers (DROL), and hyper-reflective foci (HRF) at 1-month OCT. Five patients experienced a slight increase in intraocular pressure (IOP), which was successfully managed with topical medication. Conclusions: Topical therapy alone can be a valuable option for post-PPV CME in approximately 50% of patients. Significant visual recovery and macular thickness reduction at 12 months demonstrated that DEX implants can be a safe and effective second-line treatment for pseudophakic patients with post-PPV CME and who are refractory to medical therapy. Early post-surgical OCT biomarkers may indicate a more severe CME that might benefit from the steroid implant.


  • Open Access

    Intraoperative OCT-Guided Selective Epiretinal Membrane (ERM) Peeling Versus ERM and Internal Limiting Membrane Peeling for Tractional Macular Edema in Diabetic Eyes

    by Francesco Pignatelli, Alfredo Niro, Pasquale Viggiano, Giacomo Boscia, Giuseppe Addabbo, Francesco Boscia, Cristiana Iaculli, Ermete Giancipoli

    Background and Aim: Despite the abundant literature, internal limiting membrane (ILM) peeling remains a controversial topic, especially in diabetic eyes. We compared the safety and effectiveness of intraoperative optical coherence tomography (iOCT)-assisted selective epiretinal membrane (ERM) peeling with dye-assisted ERM and ILM peeling, for the treatment of tractional diabetic macular edema (tDME). Material and Methods: In this single-center retrospective study, we evaluated consecutive patients with tDME who underwent iOCT-assisted selective ERM peeling (Group A) or “dual blue” dye-assisted ERM and ILM peeling (Group B). Best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared over a 12-month follow-up. A linear mixed model analysis was performed. Results: At baseline, the two groups were comparable in terms of their demographic and clinical outcomes. No significant difference between BCVA and CMT was observed among the groups. Both groups showed significant improvement in outcomes at the last follow-up (p < 0.001), although only iOCT-assisted ERM peeling ensured significant visual gain and macular thinning (p < 0.001) one month after surgery. A significant effect of time on both outcomes (p < 0.001) and of time–treatment interaction on visual change (p = 0.02) were observed. In eight patients, macular edema recurred (Group A: two patients; Group B: six patients) and was managed with an intravitreal dexamethasone implant. In Group A, one patient developed a recurrence of ERM without the need for reoperation. Conclusions: iOCT-assisted ERM removal may be as effective as dye-assisted ERM and ILM peeling to treat tDME. Additionally, it ensures a quicker recovery of visual function and macular thickness. The observed ERM recurrence within the 1-year follow-up was mild and did not necessitate additional surgery.


  • Open Access

    Twelve-Months Outcomes and Optical Coherence Tomography (OCT) Biomarkers After Intravitreal Dexamethasone Implant in Pseudophakic Eyes with Post-Vitrectomy Cystoid Macular Edema (CME), Refractory to Medical Therapy

    by Francesco Pignatelli, Alfredo Niro, Giuseppe Addabbo, Pasquale Viggiano, Giacomo Boscia, Maria Oliva Grassi, Francesco Boscia, Cristiana Iaculli, Giulia Maria Emilia Clima, Antonio Barone, et al.

    Background: To evaluate the incidence of postsurgical cystoid macular edema (PCME) after small-gauge pars plana vitrectomy (PPV) for different retinal pathologies and to assess the role of optical coherence tomography (OCT) biomarkers to guide treatment decision in patients with PCME, refractory to medical therapy. Materials and Methods: Medical records of consecutive pseudophakic patients, who underwent PPV for different retinal pathologies, were retrospectively evaluated in this single center, uncontrolled study. The incidence of post-PPV CME was assessed in this population. Eyes that presented with post-PPV CME within the first 2 months after surgery were considered for further evaluation. A minimum follow-up of 12 months, history of previous cataract surgery performed not earlier than 1 year before PPV, the availability of full clinical and OCT data at 1, 3, 6, 9 and 12 months after PPV, constituted the minimal requirements to be included in the 12-months assessment. Mean best corrected visual acuity (BCVA; LogMAR) together with mean central macula thickness (CMT; m) change, and response to different treatments (medical therapy and dexamethasone intravitreal implant) were evaluated. The impact of specific clinical and structural OCT biomarkers on the exposure to dexamethasone (DEX) intravitreal treatment was assessed. Eventual ocular and non-ocular adverse events, potentially related to the treatment, were investigated as-well. Results: Of 346 pseudophakic patients (352 eyes) enrolled in the study, 54 (54 eyes) developed CME within the first 2 months after PPV (incidence of 15.3%). After the exclusion of 6 subjects, the remaining 48 pa-tients were dimed eligible for the 12-months analysis. Preoperative mean BCVA (1.44 ± 0.99 LogMAR) sig-nificantly improved to 0.32 ± 0.37 LogMAR at 12 months (P< 0.001). Mean baseline CMT of 347 (± 123.5) m, significantly decreased to 290 m (± 80.4; P=0.003) by the end of the FU. Twenty-five eyes (52%) re-quired one or more DEX intravitreal implants for CME, refractory to topical therapy. The correlation analy-sis disclosed the existence of significant correlations between mean CMT values at different time points of the FU. Additionally, patients who required intravitreal therapy at months 3 and 9, were more likely to present with the following features at 1 month OCT: intraretinal fluid (IRF), disorganization of inner retinal layers (DRIL), disorganization of outer retinal layers (DROL) and hyperreflective foci (HRF). No major safe-ty issues arose. Conclusion: Topical therapy alone can be a valuable option for post-PPV CME in approximatively 50% of pa-tients. Significant visual acuity recovery and CMT reduction at 12 months, demonstrated DEX intravitreal implant can be a safe and effective second-line treatment for pseudophakic patients with post-PPV CME, refractory to medical therapy. The presence of specific OCT biomarkers may indicate a more severe CME that might benefit from the intravitreal therapy.